A Phase 3 interventional study of Secukinumab and Placebo in Ankylosing Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 11th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Tongji Hospital · Sites in China
Ages 18–80
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 20 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
21 studies in Spondylitis, Ankylosing by Novartis: 2 open now, 2 under way, none of them phase 3. Of 19 finished, 17 (89%) have results posted.
Among the 21 studies in Spondylitis, Ankylosing by Novartis, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 12th registered.
Novartis’s Spondylitis, Ankylosing studies by the year they started, since 2009.
1 of the studies testing secukinumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Spondylitis, Ankylosing:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety up to Week 52.
This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design. A screening period running up to 10 weeks before randomization was used to assess eligibility, followed by 52 weeks of treatment.
At baseline, subjects were randomized to one of the two treatment groups:
The subjects were stratified at randomization according to the region (China and non-China). Approximately 70% of randomized subjects were from China (327 Chinese subjects) in order to evaluate the efficacy and safety in this subject population. No more than 30% TNFα inhibitor inadequate responders (TNF-IR) subjects were to be enrolled in the study.
Starting at Week 16, all subjects switched to open-label secukinumab 150 mg, including all placebo subjects; however, all subjects and investigators/site staff remained blinded to the original randomized treatment group assignment (150 mg vs placebo). Study treatment continued up to Week 48.
An end of treatment visit was done 4 weeks after last study treatment administration and a post treatment follow-up visit was done 12 weeks after last study treatment administration for all subjects (regardless of whether they completed the entire study as planned or discontinued prematurely).
Subjects were instructed in detail how to self-administer the s.c. injection using PFS. Each injection was administered into an appropriate injection site of the body (thighs, arms, or abdomen). All injections were performed at the study site. Site personnel administered the injections to subjects who were not able to, or felt insecure to self-administer. Rescue medication was not allowed until Week 20. However, subjects who were deemed by the investigator not to be benefiting from the study treatment based on safety and efficacy assessments or for any reason of their own accord were free to discontinue participation in the study at any time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or non-pregnant, non-lactating female patients at least 18 years of age
Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS:
Exclusion Criteria:
Chest X-ray or MRI with evidence of ongoing infectious or malignant process
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 150 mg s.c. Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16
Drug: Secukinumab
Placebo s.c.
Drug: Placebo
Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment.
Also known as: AIN457
Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)
ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain
Time frame: Week 16
The Proportion of Participants Who Achieve an ASAS40 Response
ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Change in hsCRP Over Time
hsCRP is measured as a marker of inflammation from blood samples during the study The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: Change from baseline to Week 16. The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Percentage of Participants Who Achieve an ASAS 5/6 at Week 16
The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: Week 16: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Participants With BASDAI Response at 16 Weeks
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16
The Physical Component Summary (PCS) SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Change in ASQoL Score Over Time
The Ankylosing Spondylitis Quality of Life (ASQoL) is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis. Each statement on the ASQoL is given a score of "1" or "0". A score of "1" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).
Time frame: change from baseline to Week 16
The Proportion of Patients Who Achieve an ASAS Partial Remission
The The Assessment in SpondyloArthritis International Society (ASAS) partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10 The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
Time frame: Week 16
The majority of subjects completed 52 weeks of treatment. After Week 16 all participants originally assigned to placebo switched to AIN457 150 mg s.c. Four out of the 153 assigned to the placebo group discontinued before Week 16.
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 305 | 153 |
| Completed | 278 | 142 |
| Not completed | 27 | 11 |
| Withdrew: Adverse event | 9 | 2 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Withdrawal by subject | 12 | 4 |
| Withdrew: Technical problems | 1 | 0 |
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 280 | 139 |
| Completed | 276 | 134 |
| Not completed | 4 | 5 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain
| Participants | Secukinumab | Placebo |
|---|---|---|
| The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria) | 178 | 56 |
ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| Participants | Secukinumab | Placebo |
|---|---|---|
| The Proportion of Participants Who Achieve an ASAS40 Response | 138 | 27 |
hsCRP is measured as a marker of inflammation from blood samples during the study The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| mg/l | Secukinumab | Placebo |
|---|---|---|
| Change in hsCRP Over Time | -11.78 ± 22.919 | -0.79 ± 20.023 |
The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieve an ASAS 5/6 at Week 16 | 50.5 (44.7 to 56.3) | 19.2 (13.3 to 26.7) |
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| percent of participants | Secukinumab | Placebo |
|---|---|---|
| Participants With BASDAI Response at 16 Weeks | 41.7 (36.0 to 47.6) | 22.6 (16.3 to 30.4) |
The Physical Component Summary (PCS) SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| percent of participants | Secukinumab | Placebo |
|---|---|---|
| Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16 | 71.8 (66.3 to 76.7) | 61.1 (52.7 to 68.8) |
The Ankylosing Spondylitis Quality of Life (ASQoL) is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis. Each statement on the ASQoL is given a score of "1" or "0". A score of "1" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).
| scores | Secukinumab | Placebo |
|---|---|---|
| Change in ASQoL Score Over Time | -4.6 ± 4.98 | -2.6 ± 4.28 |
The The Assessment in SpondyloArthritis International Society (ASAS) partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10 The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.
| percent of participants | Secukinumab | Placebo |
|---|---|---|
| The Proportion of Patients Who Achieve an ASAS Partial Remission | 17.7 (13.6 to 22.6) | 7.5 (4.0 to 13.4) |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment up to week 52. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any AIN457 150 mg | 0/453 (0%) | 33/453 (7.3%) | 282/453 (62.3%) |
| Placebo | 0/153 (0%) | 3/153 (2%) | 60/153 (39.2%) |
| Event | Any AIN457 150 mg | Placebo |
|---|---|---|
| Anal abscessInfections and infestations | 3/453 | 0/153 |
| PyelonephritisInfections and infestations | 0/453 | 1/153 |
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 1/453 | 1/153 |
| Acute psychosisPsychiatric disorders | 0/453 | 1/153 |
| Pneumonia mycoplasmalInfections and infestations | 2/453 | 0/153 |
| UreterolithiasisRenal and urinary disorders | 2/453 | 0/153 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/453 | 0/153 |
| Ventricular extrasystolesCardiac disorders | 1/453 | 0/153 |
| Bronchogenic cystCongenital, familial and genetic disorders | 1/453 | 0/153 |
| Deafness neurosensoryEar and labyrinth disorders | 1/453 | 0/153 |
| Event | Any AIN457 150 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 145/453 | 29/153 |
| NasopharyngitisInfections and infestations | 46/453 | 10/153 |
| DiarrhoeaGastrointestinal disorders | 35/453 | 6/153 |
| HyperlipidaemiaMetabolism and nutrition disorders | 26/453 | 1/153 |
| Hepatic function abnormalHepatobiliary disorders | 24/453 | 3/153 |
| Alanine aminotransferase increasedInvestigations | 24/453 | 3/153 |
| Mouth ulcerationGastrointestinal disorders | 18/453 | 2/153 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 18/453 | 2/153 |
| White blood cell count decreasedInvestigations | 17/453 | 0/153 |
| Urinary tract infectionInfections and infestations | 16/453 | 5/153 |
The Full Analysis Set (FAS) was comprised of all subjects from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, subjects were evaluated according to the treatment assigned to at randomization, but actual stratum, if stratified randomization was used.
| Age, Categorical(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 303 | 152 | 455 |
| >=65 years | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 53 | 21 | 74 |
| Male | 252 | 132 | 384 |
| Race/Ethnicity, Customized(participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Asian | 239 | 130 | 369 |
| White | 64 | 23 | 87 |
| Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2016 to primary completion in May 2018, 18 months.
Results were first posted in Dec 2020, 2 years 7 months after primary completion.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 18 months is below that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab